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ABSTRACT
AN ASSESSMENT OF BSA PROTEIN HYDROGEL
BIOCOMPATIBILITY IN THE VERTEBRATE
INTESTINAL TRACT
by
Ryan Garde
The University of Wisconsin-Milwaukee, 2019
Under the Supervision of Dr. Jennifer Gutzman, Ph.D.
The fields of biomedicine and pharmacology have a mission to design methods to treat
disease while minimizing adverse side effects using novel drug delivery systems. In
developing new therapeutic systems, it is crucial to test that drug delivery systems
target pathological cells and tissue and is non-toxic in healthy tissue. One promising
method for targeted drug delivery is the use of hydrogels as carriers. Here, we studied
the effects of bovine serum albumin (BSA) hydrogel consumption to assess the
potential for hydrogel use in treating intestinal disease via oral administration. We
investigated intestinal architecture and cell populations following hydrogel treatments in
adult zebrafish. Our studies revealed that consumption of BSA hydrogels results in
normal intestinal villi architecture and bowel wall integrity. Furthermore, we
demonstrated that intestinal goblet cell appearance and abundance did not change, and
eosinophil populations remain constant over the course of treatment compared to
control tissue. We confirmed this by comparing control- and hydrogel-fed tissue to
tissue with chemically-induced inflammation. This study is important for the future
development of biocompatible drug delivery systems using hydrogels.
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CHAPTER 1
INTRODUCTION

A. GENERAL INTRODUCTION
In 2018 about 5.8 billion prescriptions were dispensed in the United States alone, a
2.8% increase from 2017, and a figure that is projected to continue to rise in the coming
years (IQVIA, 2019). As the quantity of prescription drugs administered continues to
rise, increased pressure is placed on the pharmaceutical industry to improve the timeand cost-intensive processes of drug discovery and development, pre-clinical and
clinical testing, and Food and Drug Administration (FDA) approval. Bringing new
treatment options to the market requires the collaboration of academia, the
biotechnology and pharmaceutical industries, and government through every phase
from drug discovery to approval, a process which often spans 10-15 years (Paul et al.,
2010).

The rate of success is another obstacle the pharmaceutical industry faces. Of the
therapeutic compounds that entered clinical testing in the United States from 1993 to
2004, only 16% passed approval (DiMasi et al., 2010). Between 2003 and 2011, 10.4%,
or about one-in-ten drugs, successfully transitioned from the clinical testing phase to
FDA approval (Hay et al., 2014). Improvements to clinical trial experimental design and
the use of more animal models in earlier toxicology screens, with new technologies in
targeted drug delivery have been proposed to increase success rates.
1

In recent years, the use of novel drug delivery systems to spatially and temporally target
disease is one way the pharmaceutical industry has already begun to circumvent the
lengthy, costly process of drug development and approval. While the financial burden of
conventional medicine research and development has threatened the industry’s
business model and sustainability, the emergence of novel therapeutics has the
potential to reverse downward trajectory and increase margins (Gautam and Pan, 2016;
Hogan and Tangney, 2018; Kinch and Moore, 2016). More importantly, the advent of
molecular therapeutics specifically targeting diseased tissue coupled with reduced
adverse side effects has the potential to benefit public health and treatment of disease
on a global scale.

B. TARGETED DRUG DELIVERY SYSTEMS
Targeted drug delivery is the method of precise and controlled drug delivery toward a
specific site or tissue while reducing off-target effects. The conceptual foundations of
targeted drug delivery originated over 100 years ago. In the late 1800s and early 1900s
the German microbiologist, Paul Ehrlich, developed the ‘magic bullet theory’ beginning
with observations that different chemical dyes would interact with a variety of biological
structures (Ehrlich, 1878). These histological observations later served as the basis of
research in immunology where Ehrlich hypothesized that receptors had the capacity to
specifically bind to drugs similar to the toxins of various dyes. By screening various
organic compounds, he later discovered the anti-microbial drug that would be used to
treat syphilis (Ehrlich, 1910). This pioneering work was rewarded with the 1908 Nobel
Prize for Physiology or Medicine and continues to influence modern chemotherapy and
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drug discovery. These findings have remained the foundation for rapid advancements in
the biomedical and pharmaceutical industries as we continue to develop and pursue
powerful and highly-selective therapeutics to combat human disease.

Current technologies utilizing modern drug delivery methods are rapidly advancing.
Today, drug discovery represents fields in pharmacology and biotechnology responsible
for identifying and testing potential therapeutic candidates for the treatment of diseases.
One of the earliest steps in the drug discovery process is target selection (Paul et al.,
2010). A target in this context can be defined as a biochemical molecular structure;
most often an enzyme, receptor, channel, or transporter; that a drug will interact with
and consequently have a clinical effect (Imming et al., 2006). Therefore, much of
successful management and treatment of disease is dependent on the efficiency and
effectiveness of the drug-target interaction, and the route in which it is delivered. Many
factors can be affected by the route of drug delivery including release time, metabolism,
absorption, toxicity, and target specificity. Additionally, as the discovery of new
molecules and agents emerge for therapeutics, challenges in understanding effective
and safe drug delivery routes are also created.

Therefore, targeted drug delivery systems are continuously being employed and newly
engineered in efforts to manage and increase efficacy of therapeutics and site-specific
actions. This approach to drug delivery has shown promise over the last decades of
research but the pharmaceutical industry still faces challenges with optimization of
these systems. In theory, in vivo targeted drug delivery systems distribute precise
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therapeutic concentrations exclusively to diseased cells or tissue. However, this has
been an obstacle because drug delivery has proven difficult to control by two primary
reasons, target selection and mode of delivery.

The major hurdle in targeted drug delivery is determining methods that maximize
selective activity in pathological cells or tissue with high affinity while minimizing its
introduction to healthy tissue. Advancements in DNA sequencing and completion of the
human genome have facilitated deeper understanding of the genetic basis of disease.
This allowed researchers to pinpoint expression patterns in diseased organ systems
and direct efforts in a ligand-targeted drug delivery approach (Choi et al., 2009; Worthey
et al., 2011). Often though, detectable expression patterns are variable in patients with
the same disease, suggesting targeted delivery could be more beneficial in a
personalized medicine approach. Additionally, biomarkers located in pathological tissue
are often not restricted to the targeted tissue type and can lead to off-target or global
effects (Bae and Park, 2011). Regarding modes of targeted delivery, conventional
routes of administration remain problematic with respect to drug stability and
degradation rates (Goldberg and Gomez-Orellana, 2003). For example, while oral
administration has long been the primary and preferred route, proteolysis by digestive
enzymes, patient-to-patient disparities in gastric pH, and unique microbiota
environments within the small intestine leads to decreased drug permeability across the
intestinal epithelia and consequently, limited bioavailability and diminished targeting
(Banerjee et al., 2016). These obstacles highlight some of the major difficulties
contributing to the instability of targeted delivery systems.
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Strategies and types of targeted drug delivery
The crucial components in development of drug delivery systems are to specifically
deliver therapeutics to target regions, minimizing off-target and toxic effects, and
retaining bioavailability and compatibility in a complex organism. Recently, there has
been an increasing variety of strategies that show promise for the targeted release of
therapeutics to combat disease. Currently, there are a variety of strategies employed to
improve targeted drug delivery technologies that fall into three categories: passive,
inverse, and active targeting. Passive delivery systems exploit the body’s
reticuloendothelial system (RES) and allow for the accumulation of drugs in those
regions, primarily the liver and spleen when the delivered drug reaches system
circulation (Almeida et al., 2011). These delivery systems are mainly utilized and
designed to target hepatic and lymphatic tissues. On the cellular level, the mononuclear
phagocytic system (MPS) is made up of monocytes and macrophages. Drugs targeted
toward the MPS are taken up into cell bodies within this system to carry out their
therapeutic function aimed toward the adaptive immune system (Chrastina et al., 2011).
Utilization of drugs for passive targeting is primarily delivered to the therapeutic site by
polyethylene glycol (PEG)-coated nanoparticle attachment or conjugation, allowing the
delivered drug to remain in circulation for extended periods of time without clearance
(Veronese and Pasut, 2005). Inverse targeting delivery systems utilize a similar
approach to passive systems, but instead specifically target the RES or MPS for
saturation using lipid-based carriers. This allows for an administered drug to
concentrate in a desired area of the body normally deposited in the RES for clearance
(Muro, 2012). Lipid-based carrier technology has been used for enhanced
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biodistribution of DNA-targeting chemotherapeutics (Ghosh et al., 2016) and to increase
intestinal bioavailability for oral administration (Goncalves et al., 2016). The most well
characterized delivery system is active targeting. While passive and inverse targeting
strategies are based on the length of time the pharmaceutical carrier remains in
systemic circulation and the drugs accumulation at its pathological site, active targeting
design relies on the attachment of specific therapeutic ligands to carriers for recognition
and binding of cells in pathological tissue (Muro, 2012).

Targeted drug delivery for inflammatory bowel disease
Inflammatory bowel disease (IBD) is a chronic autoimmune disorder affecting the
digestive tract. Genetic predisposition, diet, and environmental factors are known to play
important roles in IBD pathogenesis, with over 3 million people in the United States
having received diagnosis (Dahlhamer et al., 2016; Jostins et al., 2012). Ulcerative
colitis and Crohn’s disease are two forms of IBD and are characterized by dysfunctional
interactions between the host and resident enteric bacteria. Severe interactions
between host and the microbiota contribute to aberrant immune responses that
compromise the intestinal epithelial barrier and disrupt healthy gut homeostasis.
Conventional therapies for IBD are limited and designed to systemically target the
immune system. These treatments include immunomodulation and vaccines, and while
these treatments can maintain episodes of remission, they often induce significant
adverse systemic effects (Celiberto et al., 2018). Additionally, around 70% of IBD
patients require surgical intervention (Hua et al., 2015). Therefore, alternative
therapeutic strategies utilizing targeted drug delivery aim to enhance bioavailability and
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minimize systemic and off target effects are being developed to improve quality of life
and prevent recurrence of symptoms.

There are many challenging factors that need consideration for intestinal targeted drug
delivery. First, digestive system transit time should be considered for site-specific
delivery. Small intestine transit time is 2-6 hours generally and vary significantly in the
colon (5-70 hours). In patients with IBD, transit time has been shown to be delayed
compared to healthy individuals (Rana et al., 2013). Changes in luminal pH is also
important in determining effective drug delivery to the GI tract. In healthy individuals, pH
rises to pH 6 in the duodenum from the highly acidic stomach and continues to increase
through the small intestine to pH 7.4 in the ileum. Colonic pH decreases below pH 6 at
the cecum and again slowly rises over pH 6.7 in the terminal rectum. With IBD there is
little change in small intestine pH, but the colon is significantly lower from pH 5.5 in the
proximal and as low as pH 2.3 in the distal colon (McConnell et al., 2008). Lastly, the
microbiome is a crucial aspect in assessing approaches for treatment of IBD where an
estimated 500-2000 distinct bacterial species contributing to digestion, metabolism, and
health reside within the GI tract (Sartor, 2008). While there is little evidence showing
reduced bacteria load in IBD patients, studies show decreased bacterial diversity which
is thought to contribute to bacterial permeability, mucosal inflammation, and alterations
in digestive physiology (Linskens et al., 2001).

Improvements to delivery systems for effective release at therapeutic sites in IBD
patients have begun to account for all of these factors. Nanoparticle systems have been
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engineered to both passively and actively target sites of inflammation. For example,
reduced size-dependent systems have been shown to allow for the selective delivery of
therapeutics to inflamed epithelia and immune cells and avoiding recognition and rapid
elimination (Beloqui et al., 2013). Other strategies have exploited changes in pH levels
for site-specific delivery. Based on the site of inflammation these carrier systems can be
designed with polymeric, biodegradable coatings that dissolve in a pH-dependent
manner for drug delivery specifically to small intestinal tissue where pH is generally
unaltered in patients with IBD, or for dissolution and release of therapeutics within the
colon at significantly lower pH (Asghar and Chandran, 2006). Interestingly, intestinal
inflammation and depletion of the mucosal layer results in build-up of eosinophils,
proteins, and antimicrobial peptides that carry a positive charge (Ramasundara et al.,
2009; Tirosh et al., 2009). In vivo studies have already shown promising results utilizing
negatively-charged delivery systems to adhere to regions with positively-charged buildup in colitis murine models (Beloqui et al., 2013). Another unique system has emerged
for IBD drug delivery using negatively-charged carriers in the form of hydrogels. In one
study, the commonly-used corticosteroid dexamethasone (Dex) was encapsulated in
negatively-charged hydrogel polymer fibers and favorably adhered to inflamed intestinal
mucosa over healthy tissue (Zhang et al., 2015). In addition, administration was
performed in two murine colitis models exhibiting different systems, and both result in
decreased systemic exposure compared to Dex alone. This novel system strategy
demonstrated selective therapeutic release at sites of inflammation with reduced
systemic absorption using hydrogel drug delivery.
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C. HYDROGELS IN DRUG DELIVERY SYSTEMS
Hydrogels are three-dimensional aggregates of crosslinked polymer networks with
varying structure and characteristics (Jonker et al., 2012). Technologies have recently
emerged in therapeutic applications using hydrogels as a drug delivery system, but
study of their properties as a biological tool have been observed for over 50 years.
Hydrogels were first recognized for their capacity for rapid polymerization, ease of
manipulation, hydrophilic nature, and importantly, biocompatibility (Wichterle and LÍM,
1960). Since then, hydrogels have been studied in the variety of fields including
mechanobiology and biophysics. In these studies, the folding events and biomechanical
properties of hydrogels have been observed for the assessment of chemical and
mechanical stabilities under various conditions. Additionally, methods have been
established using force-clamp spectroscopy and rheometry for precise single-molecule
measurements of protein hydrogels (Khoury et al., 2018a; Ott et al., 2017; Popa et al.,
2013). In biomedical and pharmaceutical applications hydrogels have used for wound
healing and implanted transepithelial drug delivery (Bessa et al., 2008; Tellechea et al.,
2015). In these studies, hydrogels were engineered with varying characteristics for
precise spatiotemporal drug delivery, making them ideal for administering localized
therapeutics (Ashley et al., 2013; Tibbitt et al., 2016). Additionally, use of hydrogel drug
delivery systems have been employed via injection and surgical implantation techniques
displaying the versatile routes of administration for successful and precise targeting
(Gratton et al., 2008; Liu et al., 2008). The advances in hydrogels designed for
controlled drug delivery are expected to continue to change the approach toward safer
and more effective therapeutics.
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D. ZEBRAFISH MODEL ORGANISM
Intestinal tract development
Zebrafish (Danio rerio) intestinal formation has been characterized into three distinct
stages over the first five days of development. In stage one, the primitive gut in begins
to form around 26-30 hours post fertilization (hpf). At this stage of early development, a
single sheet of endodermal tissue extends anterior to posterior from the future mouth to
the future anus. Between 30 and 52 hpf is a period of patterning and rapid intestinal
morphogenesis and development of posterior enteroendocrine cells. Additionally, at 48
hpf digestive system accessory organs have formed and the developing lumen is
surrounded by enteric neuron and smooth muscle progenitor cells. Stage two is defined
by intestinal epithelia polarization and uniform proliferation between 52 and 76 hpf, and
the appearance of enteroendocrine cells scattered throughout the intestinal tract. In
stage three, between 76 and 126 hpf, global remodeling and epithelial differentiation
occur. In this stage, the intestinal lumen is compartmentalized into three distinct regions:
the intestinal bulb, midgut, and hindgut, and by 126 hfp the three regions of the tract are
functional. (Ng et al., 2005; Wallace et al., 2005; Wallace and Pack, 2003).

Conservation of the adult zebrafish intestinal tract
In the adult zebrafish intestinal tract there is conservation of architecture and anatomy
(Figure 1). In zebrafish, the intestine is a folded tube that takes up a large space within
the abdominal cavity. While they lack a stomach, the anterior intestinal tract in zebrafish
has an enlarged lumen, which serves as a reservoir similar to that of the mammalian
stomach (Figure 1A) This region is known as the intestinal bulb, and from anterior to
10

posterior, the midgut and hindgut. Although the zebrafish does not have the discrete
segments of its intestinal tract found in humans, there is anterior to posterior functional
homology. The innermost epithelial layer in zebrafish also lacks intestinal crypts, but
instead there are homologous folds, or villi, found along its intestinal tract (Wallace and
Peck, 2003). These folds are most abundant and larger in the anterior regions of the
zebrafish tract and decrease in size and number from anterior to posterior. Similar to
humans, there are differentiated epithelial cells within the zebrafish epithelial folds.
Enteroendocrine cells are predominately found in the anterior region, absorptive
enterocytes are located in the anterior bulb and midgut, and mucous-secreting goblet
cells are found in all regions of the intestinal tract. Additionally, while the zebrafish do
not have Paneth cells, there is evidence of microfold-like (M-like) immune cells
scattered throughout the intestinal tract (Brugman, 2016; Ng et al., 2005; Wallace and
Peck, 2003) (Figure 1B). Genomic studies in zebrafish have shown conserved
metabolic and digestive system-specific genes (Wang et al., 2010). Additionally, the
regulatory transcriptional networks of intestinal epithelial cells along the digestive tract
are conserved between zebrafish and human. It has been established that the same
regulatory networks that define the mammalian segments are conserved with the
zebrafish intestinal regions (Lickwar et al., 2017). Conservation of cellular responses to
toxicity and inflammation have also been identified in zebrafish. It has been shown that
pro-inflammatory markers tumor necrosis factor-alpha (TNFa), interleukin 1-beta (IL1B),
and matrix metallopeptidase 9 (MMP9) increase in response to inflammation in
zebrafish (Marjoram et al., 2015). These similarities in intestinal architecture, gene
expression, cell types, and inflammatory responses allow for the toxicological
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assessment of intestinal architecture disruption and expression patterns using the adult
zebrafish model.

E. THESIS STATEMENT
Can hydrogel-based drug delivery systems emerge as safe alternatives to conventional
treatment methods? This is the long-term question that initiated and drove the work in
this thesis. We aimed to understand if oral administration of BSA hydrogels would
produce intestinal inflammation and toxic effects over different treatment periods.

For this pilot investigation we utilized the adult zebrafish model to assess intestinal
toxicity and inflammation. We used the zebrafish because of its small but highly
conserved vertebrate intestinal architecture and cell types, and willingness to consume
hydrogels over an extended period of time.

We asked whether hydrogel consumption would: 1) be lethal, 2) cause changes in
overall body weight, 3) cause inflammation and disruption to intestinal architecture, and
4) result in changes to intestinal-specific cell populations, over the course of three
treatment periods. By feeding hydrogels to adult zebrafish over three treatment periods
we found that ingestion was non-lethal up to thirty days of consumption. We tracked
changes in weight over the different treatment periods and determined that overall body
weight was not affected by hydrogel ingestion when compared to controls over the
same time points. Furthermore, general observations of fish over these treatments
showed normal eating habits and behavior, and no phenotypical changes.
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We adapted previously published analyses for our assessment of intestinal tissue and
cellular populations following hydrogel treatments. Using these methods, we found that
intestinal architecture remained unaffected by hydrogel consumption over the different
treatment times. Additionally, cell populations specific to the intestinal tract were not
altered following treatment. Because we did not observe architectural or cellular
changes in hydrogel-fed animals, we analyzed the same parameters in chemically
induced zebrafish. Here, we observed disruption to intestinal villi, bowel wall, and cell
populations that we did not see with hydrogel consumption. These results suggest that
hydrogel is a non-toxic, biocompatible material that can continue be investigated for
biomedical and pharmaceutical applications.

With our study, we have shown that zebrafish are a useful model organism for testing
the potential of hydrogels as a biocompatible drug delivery system. We can build on
these findings to discover and test further applications for hydrogels as smart
pharmaceuticals for the treatment of diseases.

13

Figure 1. Conservation of digestive system architecture and intestinal cell types.
(A) The digestive system is composed of distinct but continuous organs in both the
human (left) and zebrafish (right). Each system consists of a folded tube with three
homologous regions. (B) Three principle cell types in human intestinal epithelia are
found in zebrafish. Zebrafish lack intestinal crypts, M-cells, and Paneth cells; however,
vacuolated M-like cells are thought to deliver intestinal luminal contents to immune cells.
Images adapted from (Lickwar et al., 2017; Wallace and Pack, 2003).
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CHAPTER 2
PROJECT DESIGN AND RESULTS

A. EXPERIMENTAL DESIGN
Our objective for this initial study was to test the safety of BSA hydrogels for use via
direct ingestion as a potential drug delivery system. In order to accomplish this
objective, we developed an experimental plan to feed BSA protein hydrogels to adult
zebrafish. Zebrafish were chosen due to their ease in manipulation and high
conservation of digestive system anatomy, metabolic and intestinal-specific genes, and
cellular responses to toxicity and inflammation. Following hydrogel feeding over different
time periods, animals were weighed and intestinal architecture was examined for signs
of toxicity and inflammation. We characterized bowel wall thickness, villi length, and
analyzed specific cell populations including goblet cells and eosinophils. We
hypothesized that the intestinal architecture and cellular populations would remain
normal through hydrogel treatments over different time periods. Specifically, we fed
BSA protein hydrogels to animals once a day for 1, 10, or 30 days. During the study,
animals were weighed regularly and at the end of each experiment animals were
weighed, then the intestinal tract was dissected and examined (Figure 2A). Intestinal
architecture and cell populations were examined using H&E staining and Alcian BluePAS staining (Figure 2B).
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We demonstrate that overall body weight is normal over the three different hydrogel
treatment periods. We further demonstrate that intestinal architecture is unchanged with
hydrogel consumption up to 30 days of treatment and we show normal intestinal specific
cellular populations throughout hydrogel treatments. Additionally, we generated positive
control data using previously established methods to assess induced inflammation in
the adult zebrafish intestine (Brugman and Nieuwenhuis, 2017). As expected, our
positive control induced inflammation experiments demonstrated disrupted intestinal
architecture and variations in cell populations. Our data demonstrate that consumption
of BSA hydrogels does not induce gross, toxic effects within the vertebrate digestive
tract for the times examined. These findings provide evidence toward the potential to
utilize protein hydrogels as a drug delivery technology.

16

B. MATERIALS AND METHODS
Zebrafish husbandry, maintenance and strains
Standard protocols were used for zebrafish (Danio rerio) maintenance and husbandry
(Westerfield, 2007). Wildtype AB and TgBAC(tnfa:GFP)pd1028 (Marjoram et al., 2015)
adult zebrafish were used for all experiments. Equal numbers of male and female
zebrafish were used for all experiments and treatment groups. This study was
performed under approval from the University of Wisconsin-Milwaukee Institutional
Animal Care and Use Committee.

Adult weight measurements
To obtain weight data, adult zebrafish were anesthetized using a 4% Tricaine (MS-222)
(Sigma, E10521) solution until loss of equilibrium and response to mild touch. Zebrafish
were quickly weighed before being placed back into separate post-anesthesia recovery
tanks and then returned to the husbandry system. All fish were closely monitored for
one hour after anesthesia.

BSA protein hydrogels
For all studies, bovine serum albumin (BSA) protein hydrogels were freshly made one
day prior to feeding to adult zebrafish. Hydrogels were made according to Khoury et al,
2018 (Khoury et al., 2018b). Briefly, 2 mM BSA hydrogels were prepared by dissolving
BSA powder (66.5 kDa; Rocky Mountain Biologics, BSA-BAF) in Tris solution (20 mM
and 150 mM NaCl, pH 7.4). Ammonium persulfate (APS) (Sigma, A3678) and
tris(bipyridine)ruthenium (II) chloride ([Ru-(bpy)3]2+) (Sigma, 544981) were prepared by
17

dissolving APS and [Ru(bpy)3]2+ powder into Tris to a final concentration of 1 M and
6.67 mM, respectively. 2 mM BSA solution was mixed with the solutions of APS and
[Ru(bpy)3]2+ at a volume ratio of 15:1:1. Next, the photoactive reaction mixture was
injected into 10 cm PTFE tubes (see Figure 2D). The loaded tubes were placed under a
100 W mercury lamp to prevent protein denaturation and irradiated for 30 minutes at
room temperature to polymerize the solution into the protein hydrogels (see Figure 2D).
Following polymerization, hydrogels were extruded and stored in a Tris-NaCl solution
until feeding (see Figure 2E).

Inflammation induction
To induce intestinal inflammation for positive control experiments we used oxazolone
induced inflammation by following the protocol published by Brugman and Nieuwenhuis,
2017. (Brugman and Nieuwenhuis, 2017). Briefly, oxazolone solution was prepared by
dissolving 20 mg oxazolone (4-Ethoxymethylene-2-phenyl-2-oxazolin-5-one) powder
(Sigma, E0753) in 5 mL 100% ethanol. This solution was then added to 5 mL PBS
(0.8% NaCl, 0.02% KCl, 0.02 M PO4, pH 7.3). Ethanol vehicle control solutions were
prepared as 50% ethanol solution in PBS. For induction of inflammation, zebrafish were
anesthetized in 4% Tricaine solution until loss of equilibrium and response to mild touch.
Zebrafish were placed ventral side up on a wet injection mat with system water and
ethanol control or oxazolone solutions were administered by intrarectal injection at 0.6
µL per 0.1 g zebrafish body weight using 50 mL fine tip pipette. Following injection,
zebrafish were transferred to a clean post-anesthesia recovery tank and monitored for
one hour. Fish remained in recovery tanks for the following 8 hours to allow for the

18

onset of inflammation after the injection. After 8 hours, adults were euthanized for
intestinal dissections and analyses.

Intestinal dissection and tissue collection
For intestinal dissections we followed the procedure published by Gupta and Mullins,
2010 (Gupta and Mullins, 2010). Briefly, adult zebrafish were anesthetized using a 4%
Tricaine solution and then euthanized by ice water incubation for 10 minutes. Zebrafish
were then pinned to a dissection mat through the caudal fin and eye socket. Dissections
were performed by cutting along the ventral side from the anterior anal fin to the
operculum and peeling back skin and muscle to expose the underlying organs and
digestive tract. The digestive tract was removed in its entirety and placed in PBS. For
histological analysis, tissue was placed in a 4% paraformaldehyde (PFA) (Alfa Aeser,
43368) in PBS at 4˚C. For qPCR analysis tissue was place in Trizol (Invitrogen,
15596026) and stored at -80˚C until RNA extraction.

Histology sectioning and analysis
Dissected intestinal samples were washed in PBS and fixed in 4% PFA in PBS
overnight at 4˚C. Samples were transferred to 20% sucrose in PBS overnight at 4˚C for
cryopreservation then frozen in HistoPrep embedding media (Fisher Scientific, SH75125D). Frozen 5-micron sagittal sections from the intestinal bulb and anterior midgut
regions were generated for staining procedures and analysis. Sections were stained
with either hematoxylin (Harleco, 65067-75) and eosin (Fisher Scientific, E511-100)
(H&E) to analyze tissue architecture or with Alcian Blue-Periodic acid-Schiff (PAS)
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(ThermoFisher, 87023) to evaluate intestinal cell types per the manufacturer protocols.
Stained sections were imaged using a Nikon Eclipse E4000 microscope at 10X
magnification and ToupView imaging software. For quantitative histological analysis,
measurements were taken from 6 fish per treatment group for all experiments. For
evaluation of bowel wall thickness, 15 representative measurements were taken from at
least 3 H&E stained sections per adult tissue sample. Measurements were then
averaged for each intestinal sample. For evaluation of intestinal villi length, 2-6
measurements per intestinal villi in each of 3 sections per adult tissue sample were
analyzed and averaged for each sample. We adapted an established scoring system for
Alcian Blue-PAS staining from (Brugman et al., 2009) to evaluate cell populations
(Brugman et al., 2009). For each adult intestinal sample, at least 3 sections were
analyzed for goblet cells and infiltrating eosinophils (see Table 1). Each section was
scored independently for goblet cells and eosinophils and given a score ranging from 13. The sum of the two scores was calculated and referred to as the total intestinal score
per section. All of the total intestinal scores for each section were averaged, resulting in
one overall intestinal score per sample. For quantification, overall intestinal scores were
averaged for each treatment group.

Statistical analysis
All data are shown as mean ± standard deviation. Statistical analyses were carried out
by Student’s t-test. Student’s t-tests were performed between control and hydrogel-fed
groups at individual time points and between ethanol vehicle and oxazolone treated
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adults. A P-value of p < 0.05 (*) was considered significant. All analyses were
performed using R 3.5.1 software.
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C. RESULTS
Generation of BSA hydrogels
In order to test for hydrogel-associated toxicity following ingestion, bovine serum
albumin (BSA) protein hydrogels were generated the day before feeding for all
experiments. We generated hydrogels daily to ensure that the treatment was consistent
over each treatment period. We generated BSA hydrogels in a photoactive redox
reaction for polymerization as published in Khoury et al, 2018 (Khoury et al., 2018b).
The photoactive BSA-polymerization mixture was injected into 10 cm PTFE tubes
(Figure 2C). The loaded tubes were placed under a 100 W mercury lamp to prevent
protein denaturation and irradiated for 30 minutes at room temperature to polymerize
the solution into the protein hydrogels (Figure 2D). Following polymerization, hydrogels
were extruded and stored overnight at 4˚C before feeding in a Tris-NaCl solution (Figure
2E). For all hydrogel treatments, adult fish consumed 5 µL of 2 mM BSA hydrogel each
day. Adult zebrafish readily ate the BSA hydrogels over the course of all treatments
(Supplemental Video 1). This observation suggested to us that the hydrogels were not
perceived as toxic by the hydrogel-fed adult animals.

Overall body weight does not change with hydrogel consumption
We first assessed the effects of hydrogel consumption on overall body weight (Figure
3). In the control diet condition, adult wild-type zebrafish were fed a normal diet twice
daily and in the test condition, adult zebrafish were fed a BSA protein hydrogel once
daily and their normal diet once daily. Fish were fed the control or hydrogel diets for 1
day, 10 days, or 30 days. To determine if overall body weight was affected by this
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regimen, fish were anesthetized and weighed pre-treatment (Day 1), again at the
halfway point for the 10- and 30-day studies (Day 5 and Day 15, respectively), and
finally post-treatment for all groups prior to sacrificing the animals and collecting
intestinal tissue for further analysis (Figure 3).

No significant differences in body weight were found between control and hydrogel-fed
fish after 1 day, over 10 days (Figure 3A), or 30 days (Figure 3B; 1-day study not
shown). Additionally, upon observation of hydrogel-fed animals, we did not detect any
changes in feeding habits, swimming behavior, or social behavior. We did not observe
phenotypic changes in emaciation, pigment changes, or decreased opercular
movement. These data demonstrate that ingestion of hydrogels over the specific time
points examined is non-lethal and does not compromise animal weight or behavior.
These results suggest that ingestion of BSA hydrogels is not grossly toxic and that
hydrogel ingestion does not have a significant effect on the metabolic state of the
animals.

Analysis of intestinal villi structure and bowel wall thickness following hydrogel
treatment
In order to assess the effect of hydrogel consumption on intestinal architecture, we used
H&E histological analysis of dissected intestinal tissue from control-fed, hydrogel-fed,
and positive control induced inflammation samples. Intestinal damage has previously
been characterized in zebrafish using bowel wall thickness and intestinal villi length in
chemically-induced inflammatory models (Brugman et al., 2009; Geiger et al., 2013).
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We used this method of analysis to examine intestinal villi length and bowel wall
thickness in control-fed and hydrogel-fed animals after 1, 10, and 30 days of feeding,
and to compare these results with our analysis of villi length and bowel wall thickness in
induced inflammation positive controls. These results are shown in Figure 4 with
representative H&E images and quantification.

After 1-day hydrogel treatments (one feeding), villi lengths were the same in the
hydrogel-fed tissue compared to controls (Figure 4A-B, I). In 10-day hydrogel-fed
samples villi lengths were also the same between hydrogel-fed tissue and controls with
no significant difference detected when quantified (Figure 4C-D, I). Following the 30-day
hydrogel treatment, villi length of hydrogel-fed tissue was normal compared to controlfed (Figure 4E-F, I). Due to the lack of effect with hydrogel-feeding we wanted to
confirm our ability to detect abnormal intestinal architecture and inflammation.
Therefore, we used a well-established method of oxazolone injection to induce intestinal
inflammation. We found that in both ethanol and oxazolone-induced positive control
samples, there was noticeable disruption to intestinal villi including a loss of villi and
decrease in length (Figure 4G-I). In addition, we quantified a significant decrease in villi
length between ethanol vehicle and oxazolone treatments in the positive controls.
These results are consistent with previous reports in chemically induced zebrafish
models showing disruption in intestinal epithelial integrity (Brugman et al., 2009).
Therefore, results from our positive controls confirmed the observation that hydrogel-fed
samples have normal tissue villi length up to 30 days of treatment.
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It has been established that the thickness of the bowel wall will increase due to
inflammation (Brugman et al., 2009). Therefore, we next measured bowel wall thickness
in control, hydrogel-fed, and inflammation induced positive control samples using H&E
stained sections (Figure 4). For the 1-day treatment period we did not observe changes
in bowel wall thickness between control and hydrogel-fed tissue (Figure 4A-B, J).
Surprisingly, the 10-day hydrogel-fed bowel wall tissue was significantly thicker than
that of 10-day controls (Figure 4C-D, J). The difference in bowel wall thickness at this
time point may have been due to the small sample size, the size of animals independent
of the treatment, or an acute response to hydrogel consumption after 10 days. In the 30day treatment group, bowel wall thickness was normal between control and hydrogelfed samples (Figure 4E-F, J). As expected, observations of ethanol and oxazoloneinduced samples showed an overall increase in bowel wall thickness when compared to
control- and hydrogel-fed at 1, 10, or 30 days of treatment (Figure 4G-H, J), again
indicating ethanol alone is toxic to the intestinal epithelia and confirming the
inflammatory response of the bowel wall to injury (Figure 4G-H, J). Together, these data
demonstrate an overall non-toxic response to protein hydrogel consumption after 30
days of treatment with minimal disruption to bowel wall thickness, villi architecture, and
overall luminal structure.

Examination of intestinal cell types following hydrogel treatment
Following our assessment of intestinal architecture, we wanted to test the effect of
hydrogel consumption on cell types within the intestinal tract. To test this we performed
detailed analysis of the appearance and number of mucus-producing goblet cells in
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intestinal villi, and the presence of inflammatory-responsive eosinophils within the bowel
wall and along villi. Variations in goblet cell appearance and number and increases in
eosinophil infiltration have been shown to be characteristic of an intestinal inflammatory
response in zebrafish colitis models (Brugman et al., 2009). Therefore, we adapted this
previously published scoring system to assess and quantify goblet cells and eosinophil
infiltration in control-fed, hydrogel-fed, and positive control tissue samples. To perform
these experiments, we stained intestinal sections from 1, 10, and 30 day treated
samples, and positive control samples with Alcian Blue and PAS. Alcian Blue allows for
observation of goblet cells, and when counterstained with PAS allows for visualization of
infiltrating eosinophils (Brugman et al., 2009). An overall intestinal score was calculated
for each treatment group by assessing goblet cell appearance and the infiltration of
eosinophils in each sample (Table 1). Each treatment sample was scored independently
for goblet cells and eosinophils (each with a score ranging from 1-3). The sum of the
two scores was calculated and averaged per sample resulting in an overall intestinal
score (Figure 5).

Within the intestinal tract in 1-day control and hydrogel-fed samples, we observed
normal intestinal goblet cells lined along villi and minimal PAS-positive eosinophils in
the bowel wall (Figure 5A-B, I). We observed a similar cell population pattern with the
10-day treatments (Figure 5C-D, I). Finally, as we hypothesized, the 30-day control and
hydrogel-fed samples had normal goblet cells and eosinophil populations (Figure 5E-F,
I). Similar to our observation in H&E stained tissue, Alcian Blue-PAS-stained ethanol
and oxazolone-induced positive control samples showed severe disruption and
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widening of villi, variations in goblet cell number and increased clusters of eosinophils
(Figure 5G-H, I). Quantification using the scoring system described in Table 1
demonstrated that the overall intestinal score in chemically induced tissue was
increased compared to control and hydrogel-fed tissue at all timepoints. Significant
differences between control-fed and hydrogel-fed intestines at 1, 10, or 30 days of
consumption were not detected (Figure 5I).

Summary
Together, these data indicate that consumption of BSA protein hydrogels results in
minimal disturbance to adult zebrafish gut architecture, goblet cell, and eosinophil cell
populations. Additionally, our positive control results are supported by previous work in
chemically induced models using similar techniques and scoring systems to evaluate
intestinal disturbances (Brugman et al., 2009; Geiger et al., 2013). Our evaluations of
villi length, bowel wall thickness, intestinal cell populations support our hypothesis that
hydrogel consumption is non-toxic and does not grossly affect intestinal tract integrity.
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Figure 2. Experimental outline, tissue analyses, and hydrogel polymerization. (A)
Experimental outline of hydrogel treatments, intestinal dissections, and sample
preparation for analysis. (B) Intestinal bulb-anterior midgut tissue was used for H&E and
Alcian-Blue-PAS staining techniques for all experiments. Posterior midgut-hindgut
tissue was used for TNFa expression analysis. (C) 2 mM BSA, ammonium persulfate
(APS, (NH4)2S2O8)) and ([Ru(bpy)3]2+) were mixed for hydrogel polymerization. (D)
Representative hydrogel mixture before (top) and after (bottom) 30-minute light
exposure for complete polymerization. (E) Representative polymerized 2 mM BSA
hydrogel stored in Tris-NaCl used for treatments. (D-E) Images adapted from Khoury et
al., 2018. Scale bar: 1 cm.
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Figure 3. Mean body weight of adult zebrafish during hydrogel treatments. (A)
Average body weight of control-fed (green) and hydrogel-fed (blue) zebrafish before,
during, and after 10-day treatment. (B) Average body weight of control-fed (green) and
hydrogel-fed (blue) zebrafish before, during, and after 30-day treatment. The same six
zebrafish are represented in each condition. Data points represent the average weights
for each condition. Data are represented as mean±s.d. Control-fed error bars, grey.
Hydrogel-fed error bars, black. n=6 for all conditions.
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Figure 4. H&E staining and quantification of intestinal architecture. (A-F)
Representative H&E stain after 1 day (A, B), 10 days (C, D), and 30 days (E, F) of
control- and hydrogel-fed treatments. (G, H) Representative H&E stain of ethanol
vehicle (G) and oxazolone-induced inflammation (H) tissue. (I) Quantification of
intestinal villi length for each condition. Arrowed lines in A-H indicate representative villi
length measurements. (J) Quantification of bowel wall thickness for each condition. Bar
lines in A-H indicate representative bowel wall measurements. Data represented as
mean±s.d. *P<0.05. Scale bars: 50 µm. n=6 for all conditions.
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Parameter

Score 1

Score 2

Score 3

Goblet Cell
Appearance

Dense, distinctive
along villi edges

Scattered along villi
edges, some
indistinct

Few and
indistinct, or
complete loss of
cells in villi

Infiltration of PASpositive
Eosinophils

Some scattered
cells, few present
in villi (<3)

Clusters in some villi
and at the base of
folds

Large clusters in
several villi and at
base of folds

Table 1: Intestinal cell type scoring parameters. Scoring method to quantify
intestinal-specific cell types following hydrogel and positive control treatments in Alcian
blue-PAS stained tissue. A score of 1-3 is assigned for goblet cell appearance and
separate score of 1-3 is assigned for infiltration of eosinophils assessed in each sample.
Distinct goblet cells were characterized by circular cells along the villi. Clusters of
infiltrating eosinophils were characterized by groups of 3 or more cells within close
proximity. Total intestinal score is the sum of the Goblet Cell Appearance score and
Infiltration of PAS-positive Eosinophils score (possible range = 2-6).
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Figure 5. Alcian Blue-PAS staining and intestinal score for goblet cells and
infiltrating eosinophils. (A-F) Representative Alcian Blue-PAS stain after 1 day (A, B),
10 days (C, D), and 30 days (E, F) of control- and hydrogel-fed tissue. (G, H)
Representative Alcian Blue-PAS stain of ethanol vehicle (G) and oxazolone-induced
inflammation (H) tissue. (I) Cumulative intestinal score for each condition. Asterisks in
A-H indicate representative goblet cells. Arrowheads in A-H indicate representative
PAS-positive eosinophils. Data represented as mean±s.d. All comparisons between
treatment groups were not significant. Scale bars: 50 µm. n=6 for all conditions.
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CHAPTER 3
CONCLUSIONS, DISCUSSION, AND FUTURE DIRECTIONS

A. CONCLUSIONS AND DISCUSSION
The overall objective of this project was to evaluate the effects produced by
consumption of bovine serum albumin (BSA) protein hydrogels on intestinal epithelium
using the adult zebrafish as a model. This project served as a pilot study in our longterm research initiative to develop and test protein hydrogels as a targeted drug delivery
system for the therapeutic treatment of intestinal disease, in particular, inflammatory
bowel disease (IBD). We hypothesize that hydrogels can be engineered to specifically
adsorb and bind to aberrantly-generated antibodies or antibody-tagged microorganisms
and pathogens within the gastrointestinal tract for clearance.

In the pilot study presented here, we tested hydrogels for potential toxicity. Adult
zebrafish were fed control diet or BSA hydrogels for 1, 10, and 30 days (Chapter 2,
Figure 3). We examined body weight at the beginning, middle, and end of the study and
found that overall body weight was not affected by hydrogel consumption. Next, we
focused on intestinal tissue histology following treatments at each time point. We found
that intestinal villi length was unaffected by hydrogel treatment compared to controls.
Bowel wall thickness was unchanged at 1- and 30-days post treatment; however, we
found increased thickness in hydrogel-fed samples after 10 days (Chapter 2, Figure 4).
Using a scoring system for intestinal goblet cells and eosinophil abundances, we found
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no changes between control and hydrogel-fed samples at all time points (Chapter 2,
Figure 5).

Together, these data suggest that BSA hydrogel consumption is non-toxic to adult
zebrafish and support the idea to further explore the potential for continued use of
hydrogels as a drug delivery system for intestinal disease therapy.

Overall body weight after hydrogel consumption
We hypothesized that consumption of BSA protein hydrogels would not alter overall
body weight. We tested this by weighing adult zebrafish before treatments, at the
halfway points for the 10- and 30-days treatments, and at the conclusion of each
treatment period. We found that total body weight remained unaffected at all time points
through the course of treatment and at the conclusion. Additionally, general
observations of the treatment groups did not reveal gross changes in phenotype or
animal behavior. There are no known data on the effects of normal diet replacement
with protein polymers, it has been shown that adult zebrafish starved for 18 days did not
have significant changes to body weight (Novak et al., 2005). Therefore, analysis of
overall body weight following treatments may not have provided the best approach in
assessing toxic effects of protein hydrogel consumption. Additional experiments are
necessary to understand the absorption, metabolism, and detoxification of protein
hydrogels within the vertebrate system and to more accurately predict their potential for
toxicity. It is known that the cytochrome p450 (CYP) superfamily of drug-metabolizing
enzymes in zebrafish are highly conserved (Saad et al., 2016). Therefore, it would be

34

beneficial to analyze the CYP family of proteins following hydrogel consumption for
continued risk assessment and toxicology screening studies. This could be done using
qPCR and Western analysis of CYP family members from intestinal epithelium, liver,
and kidney tissues.

Consumption of BSA hydrogels and intestinal damage or inflammation
We also hypothesized that ingestion of hydrogels over our experimental time points
would not induce damage to intestinal tissue or cause an inflammatory response. With
H&E staining techniques, we did not find significant changes in villi length between
hydrogel-fed and control-fed tissue. Bowel wall thickness was also unaffected at 1- and
30-days post treatment. Interestingly, at the 10-day time point bowel wall thickness was
significantly greater in hydrogel-fed tissue, suggesting a potential acute inflammatory
response after 10 days. However, this response is likely to be transient since the
animals did not demonstrate the same phenotype after the 30-day treatment.
Furthermore, power analysis using G*Power 3.1.9.4 revealed that the probability
distribution for the sample sizes in these studies was too large. This indicated that the
small sample size would result in a higher probability of obtaining a significant result.
Therefore, a larger sample size may be necessary to statistically demonstrate a
significant change in bowel wall thickness following hydrogel treatment at 10 days. After
30 days of treatment we found healthy villi architecture, bowel wall thickness, and
overall intestinal morphology.
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Our positive control experiments highlighted our ability to detect inflammation (Chapter
2, Figure 4) and were consistent with previous reports in colitis zebrafish models
chemically induced with oxazolone (Brugman et al., 2009) and 2,4,6trinitrobenzenesulfonic acid (TNBS) (Geiger et al., 2013). Consequently, our data
revealed no significant changes to gross intestinal architecture, but further analysis of
epithelial integrity is crucial in determining effects of hydrogel consumption.

In this study we demonstrated that hydrogels do not disrupt intestinal villi in healthy,
control animals, but all of these experiments were conducted using healthy, wild-type
animals. However, practical use of this therapy would be treatment of patients
experiencing inflammation. Therefore, it would be essential to test for toxicity of
hydrogel-feeding in previously damaged tissue. In order to test this, we could induce
inflammation, as demonstrated by our positive controls, in wild-type animals and
subsequently feed them BSA protein hydrogels. Then we would evaluate intestinal
epithelial integrity and cell populations. This would allow us to determine if protein
hydrogels induce any additional damage to previously inflamed tissue.

The epithelium that lines the intestine provides the physical boundary between luminal
contents and underlying tissue and is responsible for effective absorption of nutrients
from food (Walton et al., 2016). The intestinal tract is exposed to a variety of pathogens
and toxins; therefore, the epithelial barrier allows for selective uptake and regulation of
fluids and solutes while maintaining the innate and adaptive immune systems and their
responses (Sumagin and Parkos, 2015). Loss of intestinal epithelial barrier integrity can
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lead to malabsorption and insufficient nutritional uptake to sustain homeostasis and
health (Goulet et al., 2004). Therefore, it would be important to assess components of
the intestinal epithelium that maintain its barrier integrity and selective permeability
following hydrogel consumption. For example, we could use immunohistochemistry to
analyze apical cell-to-cell adherens junctions by analyzing the localization and presence
of N-cadherin. Another possibility would be to investigate tight junction proteins such as
claudin, zonula occludens-1 (ZO-1), or associated regulatory proteins such as protein
kinase C (PKC) that regulate the movement of solutes, fluids and ions (Lee, Moon and
Kim, 2018).

Goblet cell and eosinophil abundances with BSA hydrogel treatment
We found that intestinal cell types, goblet cells and eosinophils, were unaffected with
consumption of BSA hydrogels, suggesting that disruption of intestinal cell populations
in chemically induced tissue is not found in hydrogel-fed tissue. Importantly, goblet cells
secrete highly glycosylated mucins into the intestinal lumen as a first line of defense
against environmental toxins, pathogens, and microbials. While this work revealed that
there are no gross morphological changes to goblet cells following treatment, it would
be important to determine if goblet cell function is maintained during hydrogel
consumption. Three goblet cell specific proteins include, Mucin 2 (MUC2), Resistin-like
molecule-β (RELMβ), and Trefoil factor 3 (TFF3). MUC2 is the most abundant goblet
cell mucin and its secretion is crucial for the organization of the intestinal mucous layers
along the epithelial surface (Van der Sluis et al., 2006). RELMβ has been shown to
promote MUC2 secretions, inhibit intestinal parasite chemotaxis, and regulate intestinal
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inflammatory responses through macrophage and T cell activation (Nair et al., 2008).
TFF3 is a signaling molecule for epithelial repair and apoptosis resistance and
contributes to mucin crosslinking for increased mucous layer organization and structure
(Taupin, Kinoshita and Podolsky, 2000). Thus, in addition to overall morphology, qPCR,
Western analyses, and immunostaining of each component could be beneficial to
understand the impact of hydrogel consumption on goblet cell function.

38

B. FUTURE DIRECTIONS
We discovered that BSA protein hydrogels did not alter overall body weight, have
grossly toxic effects on intestinal tissue, or cause changes in specific cell types within
the digestive tract; however, the toxic threshold that hydrogel consumption may have
remains unknown. The following questions address different hypotheses regarding
hydrogel consumption and ideas to test potential toxic effects.

Does hydrogel consumption result in increased expression of pro-inflammatory
markers?
Tumor necrosis factor-alpha (TNFa) is one of the most well characterized proinflammatory cytokines that is known to have increase in expression in response to
inflammation or tissue damage (Jones-Hall and Nakatsu, 2016). Therefore, we could
examine tnfa gene expression following hydrogel feeding. We hypothesize that hydrogel
consumption over an extended time period (>10 days) would result in no change in
tnfa expression. To test this hypothesis we could use the TgBAC(tnfa:GFP)pd1028
transgenic zebrafish line. These fish provide a unique tool that would allow us to
carefully examine tnfa expression in the intestine (Marjoram et al., 2015). To assess an
inflammatory response to hydrogel consumption, we would collect intestinal tissue from
zebrafish after feeding BSA hydrogels. As a positive control we would inject
TgBAC(tnfa:GFP)pd1028 adults with either ethanol vehicle or oxazolone to induce
intestinal inflammation. Additionally, we could analyze other pro-inflammatory cytokines
that may change in response to hydrogel consumption such as interleukins il1b, il8, and
il10, which have been shown to be significantly increased in colitis induced zebrafish
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models (Brugman et al., 2009; Geiger et al., 2013). We hypothesize that with hydrogel
consumption, we would not see increased expression of pro-inflammatory cytokines.

Intestinal inflammation and epithelial damage found in immune-mediate diseases like
IBD often leads to translocation of gut microbials, gut bacteria infiltration, and T-cell
activation that can subsequently induce systemic inflammatory responses. Therefore,
we could evaluate additional organs following hydrogel treatment to test for a systemic
response to their consumption. We could perform qPCR analyses on various zebrafish
tissues for immune-associated transcription factors in addition to pro-inflammatory
cytokines. For example, we could evaluate expression of nuclear factor kappa-lightchain-enhancer of activated B cells (NF-κB) or activator protein-1 (AP-1) which are
transcription factors that are activated by cytokines, stress, and infection, and
subsequently control multiple cellular processes (Morales Fenero et al., 2016). These
experiments would allow us to have a more complete profile of inflammation in
response to consumption of hydrogels allowing us to improve their efficacy as a drug
delivery system.

At what point would BSA hydrogel consumption have toxic effects?
Since BSA hydrogel consumption was non-lethal up to 30 days of ingestion and we did
not observe significant affects suggesting toxicity, we could ask if a longer treatment
period would cause toxic effects. We hypothesize that at the concentration and volume
of BSA hydrogels fed to adult zebrafish in this study, there would not be toxicity over a
longer treatment period. To test this, we could carry out similar experiments over a
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longer time-period in a dose-responsive manner. For these studies, we could change
the concentration of proteins in hydrogels, change the composition of the hydrogel
polymers, or we could test long-term treatment in inflammation challenged animals. This
would provide data to further support hydrogel consumption as a potential drug therapy
for intestinal disease.

How are protein hydrogel polymers digested?
Currently we do not know how hydrogels are digested within the intestinal tract. This
includes how they are broken down by digestive enzymes, absorbed by intestinal
epithelial cells, or whether they are entirely cleared by the digestive system. We
hypothesize that there would be some breakdown of hydrogels as they pass through the
intestinal tract. To examine digestion of protein hydrogels we could perform qPCR
analyses of intestinal tissue for expression of digestive enzymes including serine
protease (prss1) or chymotrypsin-like (ctrl). We could also analyze expression of amino
acid transport molecules (slc15a1b) to assess protein hydrogel absorption (Tian et al.,
2015). Furthermore, we could perform RNA-sequencing for comprehensive
transcriptome profiles of control and hydrogel-fed intestinal tissue for comparison (San
et al., 2018) To test hydrogel clearance, we could isolate control and hydrogel-fed adult
zebrafish and collect waste for protein analysis using mass spectrometry (Lichtman et
al., 2013). Together, these studies would allow us to determine if hydrogel consumption
alters normal digestion, nutrient absorption, and waste excretion.
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What hydrogel composition would be beneficial for the treatment of intestinal
disease?
Administration of protein hydrogels have previously been shown to have therapeutic
effects. In zebrafish larvae, fibrin-based hydrogel injections promoted intestinal
angiogenesis (Hsieh et al., 2017). The same study also showed self-healing of ischemic
limbs in mice following intravenous injection (Hsieh et al., 2017). Therefore, we
hypothesize that hydrogels may have beneficial effects by being able to bind
endogenous proteins within the intestinal lumen for clearance. In IBD patients, epithelial
damage, intestinal inflammation, and dysregulation of the mucosal immune response
results in the production and release of Immunoglobulin A (IgA) and Immunoglobulin G
(IgG) (Mitsuyama et al., 2016). Additionally, high levels of IgA and IgG-coated bacteria
complexes have been detected in fecal matter of IBD patients (Lin et al., 2018). These
findings have the potential to be exploited using protein hydrogel technology. Our
collaborators have the capacity to synthesize protein hydrogels from diverse purified
proteins, including bacterial surface proteins (personal communication, Dr. Ionel Popa,
University of Wisconsin-Milwaukee, Department of Physics). Protein L is a bacterial
surface protein found on Peptostreptococcus magnus that binds to the light chain of
various classes of immunoglobulins with high affinity (Akerström and Björck, 1989).
Therefore, we could synthesize Protein L hydrogels and feed to challenged zebrafish.
We hypothesize that Protein L hydrogels would bind to immunoglobulins released within
the intestinal lumen. After feeding, we could collect and analyze waste to determine in
vivo hydrogel binding of intestinal antibodies. We predict that this technology has the
potential to significantly impact the treatment of intestinal inflammation and disease.
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